Zacks21d agoneutral
Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
141last 24h
874last 7d
144● bullish (7d)
99● bearish (7d)
214publishers
Zacks50d agobullish
IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva UptakeImmunityBio beat Q2 earnings and revenue estimates as record Anktiva sales and continued adoption fuel growth, with more regulatory milestones ahead.
Zacks51d agobullish
ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue EstimatesImmunityBio (IBRX) delivered earnings and revenue surprises of +11.11% and +5.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks52d agobullish
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue EstimatesStoke Therapeutics (STOK) delivered earnings and revenue surprises of -13.42% and +69.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Stocktwits57d agobullish
IBRX Stock Extends 5-Day Losing Streak — Retail Traders Pin Hopes On ‘Incredibly Strong’ Anktiva Sales And Earnings BeatInvestors are also watching for partnership or buyout catalysts as ImmunityBio expands Anktiva internationally and builds its global NK-cell platform.
Simply Wall St.108d agoneutral
3 Growth Companies With High Insider Ownership Seeing Up To 94% Earnings GrowthOver the last 7 days, the United States market has dropped by 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this context of fluctuating performance and anticipated growth, stocks with high insider ownership can be appealing as they often signal confidence from those closest to the company's operations and potential for substantial earnings growth.
Zacks140d agobullish
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue EstimatesImmunityBio (IBRX) delivered earnings and revenue surprises of -12.50% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks143d agoneutral
ImmunityBio to Report Q1 Earnings: What's in the Cards?IBRX's Q1 outlook rides on Anktiva's surging uptake, with preliminary revenues showing triple-digit growth ahead of its earnings report later this month.